![]() |
|
|
Vol. 283, Issue 2, 604-610, 1997
Department of Pharmacology, Faculty of Medicine,
University of Ottawa, Ottawa, Ontario, Canada
Dynorphin (Dyn) A and related opioid and nonopioid peptides were tested
for their ability to produce motor effects in mice. Central
(intracerebroventricular) administration of Dyn A in mice produced
marked motor effects characterized by wild running, jumping, circling
and/or barrel rolling with an ED50 value of 14.32 (95% confidence limits, 10.09-20.32) nmol/mouse. The order of potency of
the various Dyn A-related peptides and fragments in producing motor
effects was Dyn A
Dyn A-(1-13) > [Ala1]Dyn
A-(1-13)
Dyn A-(2-13) >
-Neo-End > Dyn A-(1-8)
Dyn
B
Dyn A-(2-8) >>> Dyn A-(3-8). Dyn A-(1- 5) (or Leu-Enk)
and Dyn A-(6-10) displayed no motor effect at doses up to 100 nmol/mouse. The potencies of Dyn A and Dyn A-(2-13) were not affected
by preadministration of naloxone (5 mg/kg s.c.), but the motor effects
of Dyn A-(1-13) (20 nmol/mouse i.c.v.) were significantly reduced by
coadministration of low doses (0.2-0.6 nmol/mouse) of the
N-methyl-D-aspartate (NMDA) receptor antagonists
dextrorphan, MK-801 and CPP. Dyn A was also a potent inhibitor of the
binding of the phencyclidine receptor ligand, [3H]MK-801,
to rat brain membranes, with a Ki
value of 0.41 µM. However, the order of potency of the various Dyn
A-related peptides and fragments in inhibiting [3H]MK-801
binding did not correlate with their ability to produce motor effects.
On the other hand, Dyn A and related peptides produced a significant
potentiation of the binding of the competitive NMDA antagonist
[3H]CGP-39653 to rat brain membranes, an effect that
correlated well (r = 0.91) with their potency in
producing motor effects. These results indicate that the nonopioid
motor effects of Dyn A and related peptides are structure dependent,
with Dyn A-(2-8) being the minimal core peptide for motor activity. In
addition, these effects most likely involve the participation of the
excitatory amino acid binding domain on the NMDA receptor complex.
This article has been cited by other articles:
![]() |
S. Loacker, M. Sayyah, W. Wittmann, H. Herzog, and C. Schwarzer Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors Brain, April 1, 2007; 130(4): 1017 - 1028. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Koetzner, X.-Y. Hua, J. Lai, F. Porreca, and T. Yaksh Nonopioid Actions of Intrathecal Dynorphin Evoke Spinal Excitatory Amino Acid and Prostaglandin E2 Release Mediated by Cyclooxygenase-1 and -2 J. Neurosci., February 11, 2004; 24(6): 1451 - 1458. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zimmer, E. Valjent, M. Konig, A. M. Zimmer, P. Robledo, H. Hahn, O. Valverde, and R. Maldonado Absence of Delta -9-Tetrahydrocannabinol Dysphoric Effects in Dynorphin-Deficient Mice J. Neurosci., December 1, 2001; 21(23): 9499 - 9505. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Laughlin, A. A. Larson, and G. L. Wilcox Mechanisms of Induction of Persistent Nociception by Dynorphin J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 6 - 11. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Butelman, T. J. Harris, A. Perez, and M.-J. Kreek Effects of Systemically Administered Dynorphin A(1-17) in Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 678 - 686. [Abstract] [Full Text] |
||||